Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results

Bibliography

• Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008;34(3):206-22
   PubMed Web of Science ®Google Scholar
• Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16(10):695-714
   PubMed Web of Science ®Google Scholar
• Gottlicher M, Minucci S, Zhu P, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20(24):6969-78
   PubMed Web of Science ®Google Scholar
• Bradner JE, Mak R, Tanguturi SK, Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci USA 2010;107(28):12617-22
   PubMed Web of Science ®Google Scholar
• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009;10(1):32-42
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang H, Yoon SO, HDAC-mediated deacetylation of NF-kappaB is critical for schwann cell myelination. Nat Neurosci 2011;14(4):437-41
   PubMed Web of Science ®Google Scholar
• Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005;307(5707):269-73
   PubMed Web of Science ®Google Scholar
• Buerki C, Rothgiesser KM, Valovka T, Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65. Nucleic Acids Res 2008;36(5):1665-80
   PubMed Web of Science ®Google Scholar
• Chen CS, Weng SC, Tseng PH, Histone acetylation-independent effect of histone deacetylase inhibitors on akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 2005;280(46):38879-87
   PubMed Web of Science ®Google Scholar
• Togi S, Kamitani S, Kawakami S, HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A. Biochem Biophys Res Commun 2009;379(2):616-20
   PubMed Web of Science ®Google Scholar
• Wagner JM, Hackanson B, Lubbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 2010;1(3-4):117-36
   PubMedGoogle Scholar
• Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol 2009;19(3):188-97
   PubMed Web of Science ®Google Scholar
• Bredel M, Scholtens DM, Yadav AK, NFKBIA deletion in glioblastomas. N Engl J Med 2011;364(7):627-37
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
   PubMed Web of Science ®Google Scholar
• Campos B, Bermejo JL, Han L, Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 2011;102(2):387-92
   PubMed Web of Science ®Google Scholar
• Sharma V, Koul N, Joseph C, HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J Cell Mol Med 2010;14(8):2151-61
   PubMed Web of Science ®Google Scholar
• Gensert JM, Baranova OV, Weinstein DE, Ratan RR. CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells. Neurobiol Dis 2007;26(3):671-80
   PubMed Web of Science ®Google Scholar
• Sarcar B, Kahali S, Chinnaiyan P. Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. J Neurooncol 2010;99(2):201-7
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Vallabhaneni G, Armstrong E, Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005;62(1):223-9
   PubMed Web of Science ®Google Scholar
• Robe PA, Jolois O, N'Guyen M, Modulation of the HSV-TK/ganciclovir bystander effect by n-butyrate in glioblastoma: correlation with gap-junction intercellular communication. Int J Oncol 2004;25(1):187-92
   PubMed Web of Science ®Google Scholar
• Su JM, Li XN, Thompson P, Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res 2011;17(3):589-97
   PubMed Web of Science ®Google Scholar
• Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Lett 2009;274(2):169-76
   PubMed Web of Science ®Google Scholar
• Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem 2010;45(6):2095-116
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Turner JG, HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 2009;8(4):794-801
   PubMed Web of Science ®Google Scholar
• Chen X, Wong P, Radany E, Wong JY. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 2009;24(6):689-99
   PubMed Web of Science ®Google Scholar
• Lucio-Eterovic AK, Cortez MA, Valera ET, Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008;8:243
   PubMed Web of Science ®Google Scholar
• Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 2007;13(1):23-9
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Nakayama J. Physiological roles of class I HDAC complex and histone demethylase. J Biomed Biotechnol 2011;2011:129383
   PubMedGoogle Scholar
• Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 2004;13(6):853-65
   PubMed Web of Science ®Google Scholar
• Bhat KP, Pelloski CE, Zhang Y, Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. FEBS Lett 2008;582(21-22):3193-200
   PubMed Web of Science ®Google Scholar
• Burton TR, Eisenstat DD, Gibson SB. BNIP3 (bcl-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas. J Neurosci 2009;29(13):4189-99
   PubMed Web of Science ®Google Scholar
• Sadoul K, Wang J, Diagouraga B, Khochbin S. The tale of protein lysine acetylation in the cytoplasm. J Biomed Biotechnol 2011;2011:970382
   Google Scholar
• Choudhary C, Kumar C, Gnad F, Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325(5942):834-40
   PubMed Web of Science ®Google Scholar
• Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005;363:15-23
   PubMed Web of Science ®Google Scholar
• Li L, Gondi CS, Dinh DH, Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappaB transcriptional activity. Clin Cancer Res 2007;13(7):2178-90
   PubMed Web of Science ®Google Scholar
• Kiernan R, Bres V, Ng RW, Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003;278(4):2758-66
   PubMed Web of Science ®Google Scholar
• Liu BL, Cheng JX, Zhang X, Global histone modification patterns as prognostic markers to classify glioma patients. Cancer Epidemiol Biomarkers Prev 2010;19(11):2888-96
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321(5897):1807-12
   PubMed Web of Science ®Google Scholar
• Chang CJ, Hsu CC, Yung MC, Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 2009;380(2):236-42
   PubMed Web of Science ®Google Scholar
• Inoue T, Hiratsuka M, Osaki M, SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 2007;26(7):945-57
   PubMed Web of Science ®Google Scholar
• Kito M, Maehara M, Watanabe K. Antiepileptic drugs–calcium current interaction in cultured human neuroblastoma cells. Seizure 1994;3(2):141-9
   PubMedGoogle Scholar
• Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000;37(2-3):103-10
   PubMed Web of Science ®Google Scholar
• Jung GA, Yoon JY, Moon BS, Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-ras-ERK-p21Cip/WAF1 pathway. BMC Cell Biol 2008;9:66
   PubMedGoogle Scholar
• Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999;72(3):1327-30
   PubMed Web of Science ®Google Scholar
• Bermudez-Lugo JA, Perez-Gonzalez O, Rosales-Hernandez MC, Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations. J Mol Model 2011. [Epub ahead of print]
   PubMedGoogle Scholar
• Phiel CJ, Zhang F, Huang EY, Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276(39):36734-41
   PubMed Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409(2):581-9
   PubMed Web of Science ®Google Scholar
• Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64(3):1079-86
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Khanim FL, Hayden R, Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19(10):1751-9
   PubMed Web of Science ®Google Scholar
• Benitez JA, Arregui L, Cabrera G, Segovia J. Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression. Neuroscience 2008;156(4):911-20
   PubMed Web of Science ®Google Scholar
• Das CM, Aguilera D, Vasquez H, Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007;85(2):159-70
   PubMed Web of Science ®Google Scholar
• Camphausen K, Cerna D, Scott T, Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005;114(3):380-6
   PubMed Web of Science ®Google Scholar
• Condorelli F, Gnemmi I, Vallario A, Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008;153(4):657-68
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ, Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009;27(12):2052-8
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Lamborn KR, Kuhn JG, A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: north american brain tumor consortium study 03-03. Neuro Oncol 2011;13(5):509-16
   PubMed Web of Science ®Google Scholar
• Wu SC, Zhang Y. Active DNA demethylation: many roads lead to rome. Nat Rev Mol Cell Biol 2010;11(9):607-20
   PubMed Web of Science ®Google Scholar
• Rajendran G, Shanmuganandam K, Bendre A, Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. J Neuro Oncology 2011;104(2):483-94
   PubMed Web of Science ®Google Scholar
• Foltz G, Yoon JG, Lee H, DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis. Oncogene 2009;28(29):2667-77
   PubMed Web of Science ®Google Scholar
• Perisic T, Zimmermann N, Kirmeier T, Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacology 2010;35(3):792-805
   PubMed Web of Science ®Google Scholar
• Milutinovic S, D'Alessio AC, Detich N, Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007;28(3):560-71
   PubMed Web of Science ®Google Scholar
• Papi A, Ferreri AM, Rocchi P, Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Res 2010;30(2):535-40
   PubMed Web of Science ®Google Scholar
• Sasai K, Akagi T, Aoyanagi E, O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. Mol Cancer 2007;6:36
   PubMedGoogle Scholar
• Hegi ME, Diserens AC, Gorlia T, MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003
   PubMed Web of Science ®Google Scholar
• Bosetti F, Bell JM, Manickam P. Microarray analysis of rat brain gene expression after chronic administration of sodium valproate. Brain Res Bull 2005;65(4):331-8
   PubMed Web of Science ®Google Scholar
• Li B, Zhang S, Li M, Down-regulation of GluK2 kainate receptor expression by chronic treatment with mood-stabilizing anti-convulsants or lithium in cultured astrocytes and brain, but not in neurons. Neuropharmacology 2009;57(4):375-85
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, De Bruyn C, Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 2009;23(12):2281-9
   PubMed Web of Science ®Google Scholar
• De la Cruz-Hernandez E, Perez-Plasencia C, Perez-Cardenas E, Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. Oncol Rep 2011;25(2):399-407
   PubMed Web of Science ®Google Scholar
• Frattola L, Ferrarese C, Canal N, Characterization of the gamma-aminobutyric acid receptor system in human brain gliomas. Cancer Res 1985;45(9):4495-8
   PubMed Web of Science ®Google Scholar
• Roach JD Jr, Aguinaldo GT, Jonnalagadda K, Gamma-aminobutyric acid inhibits synergistic interleukin-6 release but not transcriptional activation in astrocytoma cells. Neuroimmunomodulation 2008;15(2):117-24
   PubMed Web of Science ®Google Scholar
• Liu Q, Li G, Li R, IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol 2010;100(2):165-76
   PubMed Web of Science ®Google Scholar
• Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009;360(8):813-15
   PubMed Web of Science ®Google Scholar
• Latour I, Louw DF, Beedle AM, Expression of T-type calcium channel splice variants in human glioma. Glia 2004;48(2):112-19
   PubMed Web of Science ®Google Scholar
• Lu F, Chen H, Zhou C, Wu S. Is there a role for T-type Ca2+ channel in glioma cell proliferation? Cell Calcium 2005;38(6):593; 5; author reply 597
   PubMed Web of Science ®Google Scholar
• Panner A, Cribbs LL, Zainelli GM, Variation of T-type calcium channel protein expression affects cell division of cultured tumor cells. Cell Calcium 2005;37(2):105-19
   PubMed Web of Science ®Google Scholar
• Bertolesi GE, Shi C, Elbaum L, The ca(2+) channel antagonists mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms. Mol Pharmacol 2002;62(2):210-19
   PubMed Web of Science ®Google Scholar
• Wang Z, Xu L, Zhu X, Demethylation of specific Wnt/beta-catenin pathway genes and its upregulation in rat brain induced by prenatal valproate exposure. Anat Rec (Hoboken) 2010;293(11):1947-53
   PubMedGoogle Scholar
• Zhang X, Chen T, Zhang J, Notch1 promotes glioma cell migration and invasion by stimulating beta-catenin and NF-kappaB signaling via AKT activation. Cancer Sci 2012;103(2):181-90
   PubMed Web of Science ®Google Scholar
• Williams SP, Nowicki MO, Liu F, Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res 2011;71(16):5374-80
   PubMed Web of Science ®Google Scholar
• Bowman A, Nusse R. Location, location, location: foxM1 mediates beta-catenin nuclear translocation and promotes glioma tumorigenesis. Cancer Cell 2011;20(4):415-16
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim KH, Lee J, Wnt activation is implicated in glioblastoma radioresistance. Lab Invest 2012;92(3):466-73
   PubMed Web of Science ®Google Scholar
• Kotliarova S, Pastorino S, Kovell LC, Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 2008;68(16):6643-51
   PubMed Web of Science ®Google Scholar
• Korur S, Huber RM, Sivasankaran B, GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One 2009;4(10):e7443
   PubMedGoogle Scholar
• Miyashita K, Kawakami K, Nakada M, Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. Clin Cancer Res 2009;15(3):887-97
   PubMed Web of Science ®Google Scholar
• Knupfer MM, Hernaiz-Driever P, Poppenborg H, Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res 1998;18(5A):3585-9
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Cerna D, Burgan WE, Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 2008;14(17):5410-15
   PubMed Web of Science ®Google Scholar
• Fu J, Shao CJ, Chen FR, Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol 2010;12(4):328-40
   PubMed Web of Science ®Google Scholar
• Chen CH, Chang YJ, Ku MS, Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. J Mol Med 2011;89(3):303-15
   PubMed Web of Science ®Google Scholar
• Bacon CL, Gallagher HC, Haughey JC, Regan CM. Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase. J Neurochem 2002;83(1):12-19
   PubMed Web of Science ®Google Scholar
• Fortson WS, Kayarthodi S, Fujimura Y, Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 2011;39(1):111-19
   PubMed Web of Science ®Google Scholar
• Simboeck E, Sawicka A, Zupkovitz G, A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors. J Biol Chem 2010;285(52):41062-73
   PubMed Web of Science ®Google Scholar
• Dash BC, El-Deiry WS. Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 2005;25(8):3364-87
   PubMed Web of Science ®Google Scholar
• Ando T, Kawabe T, Ohara H, Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem 2001;276(46):42971-7
   PubMed Web of Science ®Google Scholar
• Ichiyama T, Okada K, Lipton JM, Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res 2000;857(1-2):246-51
   PubMed Web of Science ®Google Scholar
• Lehmann A, Denkert C, Budczies J, High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009;9:395
   PubMedGoogle Scholar
• Rao JS, Bazinet RP, Rapoport SI, Lee HJ. Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disord 2007;9(5):513-20
   PubMed Web of Science ®Google Scholar
• de la Iglesia N, Konopka G, Puram SV, Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 2008;22(4):449-62
   PubMed Web of Science ®Google Scholar
• Chen Q, Ouyang DY, Geng M, Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways. J Immunotoxicol 2011;8(3):210-18
   PubMed Web of Science ®Google Scholar
• Liang QC, Xiong H, Zhao ZW, Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells. Cancer Lett 2009;273(1):164-71
   PubMed Web of Science ®Google Scholar
• Hu J, Jo M, Cavenee WK, Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc Natl Acad Sci USA 2011;108(38):15984-9
   PubMed Web of Science ®Google Scholar
• Alvarez-Breckenridge CA, Yu J, Price R, The HDAC inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and IFNgamma generation. J Virol 2012;86(8):4566-77
   PubMed Web of Science ®Google Scholar
• Gotfryd K, Skladchikova G, Lepekhin EA, Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylation. BMC Cancer 2010;10:383
   PubMed Web of Science ®Google Scholar
• Lange C, Mix E, Frahm J, Small molecule GSK-3 inhibitors increase neurogenesis of human neural progenitor cells. Neurosci Lett 2011;488(1):36-40
   PubMed Web of Science ®Google Scholar
• Jonathan Ryves W, Dalton EC, Harwood AJ, Williams RS. GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord 2005;7(3):260-5
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3):157-73
   PubMed Web of Science ®Google Scholar
• Wolff JE, Kramm C, Kortmann RD, Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 2008;90(3):309-14
   PubMed Web of Science ®Google Scholar
• Morita K, Gotohda T, Arimochi H, Histone deacetylase inhibitors promote neurosteroid-mediated cell differentiation and enhance serotonin-stimulated brain-derived neurotrophic factor gene expression in rat C6 glioma cells. J Neurosci Res 2009;87(11):2608-14
   PubMed Web of Science ®Google Scholar
• Tabu K, Sasai K, Kimura T, Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 2008;18(10):1037-46
   PubMed Web of Science ®Google Scholar
• Yagi Y, Fushida S, Harada S, Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res 2010;29:149
   PubMedGoogle Scholar
• Iacomino G, Medici MC, Russo GL. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Anticancer Res 2008;28(2A):855-64
   PubMed Web of Science ®Google Scholar
• Xie C, Edwards H, Xu X, Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 2010;16(22):5499-510
   PubMed Web of Science ®Google Scholar
• Brazelle W, Kreahling JM, Gemmer J, Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS ONE 2010;5(12):e14335
   PubMed Web of Science ®Google Scholar
• Chai G, Li L, Zhou W, HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS ONE 2008;3(6):e2445
   PubMedGoogle Scholar
• Lee JH, Choy ML, Ngo L, Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 2010;107(33):14639-44
   PubMed Web of Science ®Google Scholar
• Ciusani E, Balzarotti M, Calatozzolo C, Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. Oncol Res 2007;16(10):453-63
   PubMed Web of Science ®Google Scholar
• Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005;25(4):383-97
   PubMed Web of Science ®Google Scholar
• Michaelis M, Michaelis UR, Fleming I, Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004;65(3):520-7
   PubMed Web of Science ®Google Scholar
• Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5(11):610-20
   PubMed Web of Science ®Google Scholar
• Zgouras D, Becker U, Loitsch S, Stein J. Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun 2004;316(3):693-7
   PubMed Web of Science ®Google Scholar
• Gao D, Xia Q, Lv J, Zhang H. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo. Int J Urol 2007;14(9):838-45
   PubMed Web of Science ®Google Scholar
• Deroanne CF, Bonjean K, Servotte S, Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002;21(3):427-36
   PubMed Web of Science ®Google Scholar
• Osuka S, Takano S, Yamamoto T, Histone deacetylase inhibitor, valproic acid inhibits glioma angiogenesis in vitro and in vivo in the brain. Neuro-oncol 2009;11(6):962
   Web of Science ®Google Scholar
• Kim SH, Jeong JW, Park JA, Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 2007;17(3):647-51
   PubMed Web of Science ®Google Scholar
• Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009;280(2):145-53
   PubMed Web of Science ®Google Scholar
• Kaur B, Khwaja FW, Severson EA, Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005;7(2):134-53
   PubMed Web of Science ®Google Scholar
• Qiang L, Wu T, Zhang HW, HIF-1alpha is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating notch signaling pathway. Cell Death Differ 2012;19(2):284-94
   PubMed Web of Science ®Google Scholar
• Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23(10):2411-22
   PubMed Web of Science ®Google Scholar
• Zhai GG, Malhotra R, Delaney M, Radiation enhances the invasive potential of primary glioblastoma cells via activation of the rho signaling pathway. J Neurooncol 2006;76(3):227-37
   PubMed Web of Science ®Google Scholar
• Kroonen J, Nassen J, Boulanger YG, Human glioblastoma-initiating cells invade specifically the subventricular zones and olfactory bulbs of mice after striatal injection. Int J Cancer 2011;129(3):574-85
   PubMed Web of Science ®Google Scholar
• Teodorczyk M, Martin-Villalba A. Sensing invasion: cell surface receptors driving spreading of glioblastoma. J Cell Physiol 2010;222(1):1-10
   PubMed Web of Science ®Google Scholar
• Zamecnik J. The extracellular space and matrix of gliomas. Acta Neuropathol 2005;110(5):435-42
   PubMed Web of Science ®Google Scholar
• An Z, Gluck CB, Choy ML, Kaufman LJ. Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. Cancer Lett 2010;292(2):215-27
   PubMed Web of Science ®Google Scholar
• Eyupoglu IY, Hahnen E, Trankle C, Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 2006;5(5):1248-55
   PubMed Web of Science ®Google Scholar
• Knupfer MM, Pulzer F, Schindler I, Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Anticancer Res 2001;21(1A):347-51
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007;7(10):733-6
   PubMed Web of Science ®Google Scholar
• Charles NA, Holland EC, Gilbertson R, The brain tumor microenvironment. Glia 2011;59(8):1169-80
   PubMed Web of Science ®Google Scholar
• Markovic DS, Glass R, Synowitz M, Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol 2005;64(9):754-62
   PubMed Web of Science ®Google Scholar
• Chen FX, Ren WW, Yang Y, Reciprocal effects of conditioned medium on cultured glioma cells and neural stem cells. J Clin Neurosci 2009;16(12):1619-23
   PubMed Web of Science ®Google Scholar
• Chirasani SR, Sternjak A, Wend P, Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 2010;133(Pt 7):1961-72
   PubMedGoogle Scholar
• Chen PS, Wang CC, Bortner CD, Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007;149(1):203-12
   PubMed Web of Science ®Google Scholar
• Go HS, Seo JE, Kim KC, Valproic acid inhibits neural progenitor cell death by activation of NF-kappaB signaling pathway and up-regulation of bcl-XL. J Biomed Sci 2011;18(1):48
   PubMedGoogle Scholar
• Suh HS, Choi S, Khattar P, Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. J Neuroimmune Pharmacol 2010;5(4):521-32
   PubMed Web of Science ®Google Scholar
• Baltes S, Fedrowitz M, Tortos CL, Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007;320(1):331-43
   PubMed Web of Science ®Google Scholar
• Rivers F, O'Brien TJ, Callaghan R. Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations. Eur J Pharmacol 2008;598(1-3):1-8
   PubMed Web of Science ®Google Scholar
• Tang R, Faussat AM, Majdak P, Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004;18(7):1246-51
   PubMed Web of Science ®Google Scholar
• Kortenhorst MS, Zahurak M, Shabbeer S, A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. Clin Cancer Res 2008;14(21):6886-94
   PubMed Web of Science ®Google Scholar
• Liu T, Liu PY, Tee AE, Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer 2009;45(10):1846-54
   PubMed Web of Science ®Google Scholar
• Huang X, Guo B. Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res 2006;66(18):9245-51
   PubMed Web of Science ®Google Scholar
• Fedier A, Dedes KJ, Imesch P, The histone deacetylase inhibitors suberoylanilide hydroxamic (vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol 2007;31(3):633-41
   PubMed Web of Science ®Google Scholar
• Imesch P, Dedes KJ, Furlato M, MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. Int J Oncol 2009;35(3):631-40
   PubMed Web of Science ®Google Scholar
• Cowell IG, Sunter NJ, Singh PB, gammaH2AX foci form preferentially in euchromatin after ionising-radiation. PLoS ONE 2007;2(10):e1057
   PubMed Web of Science ®Google Scholar
• Goodarzi AA, Jeggo P, Lobrich M. The influence of heterochromatin on DNA double strand break repair: getting the strong, silent type to relax. DNA Repair (Amst) 2010;9(12):1273-82
   PubMed Web of Science ®Google Scholar
• Green SR, Choudhary AK, Fleming IN. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. Br J Cancer 2010;103(9):1391-9
   PubMed Web of Science ®Google Scholar
• Sato A, Asano T, Horiguchi A, Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. Oncol Res 2011;19(5):217-23
   PubMed Web of Science ®Google Scholar
• Stander M, Dichgans J, Weller M. Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. J Neurooncol 1998;37(3):191-8
   PubMed Web of Science ®Google Scholar
• Camphausen K, Burgan W, Cerra M, Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64(1):316-21
   PubMed Web of Science ®Google Scholar
• Puerto S, Ramirez MJ, Marcos R, Radiation-induced chromosome aberrations in human euchromatic (17cen-p53) and heterochromatic (1cen-1q12) regions. Mutagenesis 2001;16(4):291-6
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004;59(4):928-42
   PubMed Web of Science ®Google Scholar
• Van Nifterik KA, Van den Berg J, Slotman BJ, Valproic acid sensitizes human glioma cells for temozolomide and gamma-radiation. J Neurooncol 2012;107(1):61-7
   PubMed Web of Science ®Google Scholar
• Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007;25(26):4051-6
   PubMed Web of Science ®Google Scholar
• Thoms J, Bristow RG. DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol 2010;20(4):217-22
   PubMed Web of Science ®Google Scholar
• Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 2009;417(3):639-50
   PubMedGoogle Scholar
• Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008;18(1):134-47
   PubMed Web of Science ®Google Scholar
• Shabason JE, Tofilon PJ, Camphausen K. Grand rounds at the national institutes of health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med 2011;15(12):2735-44
   PubMed Web of Science ®Google Scholar
• Kawano T, Akiyama M, Agawa-Ohta M, Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. Int J Oncol 2010;37(4):787-95
   PubMed Web of Science ®Google Scholar
• Otsuki A, Patel A, Kasai K, Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 2008;16(9):1546-55
   PubMed Web of Science ®Google Scholar
• Kothari V, Joshi G, Nama S, HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model. Int J Cancer 2010;126(3):733-42
   PubMed Web of Science ®Google Scholar
• Hacker S, Dittrich A, Mohr A, Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009;28(35):3097-110
   PubMed Web of Science ®Google Scholar
• Balbi A, Sottofattori E, Mazzei M, Sannita WG. Study of bioequivalence of magnesium and sodium valproates. J Pharm Biomed Anal 1991;9(4):317-21
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia 2008;49(7):1239-76
   PubMed Web of Science ®Google Scholar
• Lundberg B, Nergardh A, Boreus LO. Plasma concentrations of valproate during maintenance therapy in epileptic children. J Neurol 1982;228(2):133-41
   PubMed Web of Science ®Google Scholar
• Moody JP, Allan SM. Measurement of valproic acid in serum as the 4-bromophenacyl ester by high performance liquid chromatography. Clin Chim Acta 1983;127(2):263-9
   PubMed Web of Science ®Google Scholar
• Tomson T, Dahl ML, Kimland E. Therapeutic monitoring of antiepileptic drugs for epilepsy. Cochrane Database Syst Rev 2007(1):CD002216
   PubMed Web of Science ®Google Scholar
• Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23(6):693-720
   PubMed Web of Science ®Google Scholar
• Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother 2010;44(7-8):1287-93
   PubMed Web of Science ®Google Scholar
• Hagg S, Spigset O. Anticonvulsant use during lactation. Drug Saf 2000;22(6):425-40
   PubMed Web of Science ®Google Scholar
• Wieser HG. Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res 1991;9(2):154-9
   PubMed Web of Science ®Google Scholar
• Fischer W, Praetor K, Metzner L, Transport of valproate at intestinal epithelial (caco-2) and brain endothelial (RBE4) cells: mechanism and substrate specificity. Eur J Pharm Biopharm 2008;70(2):486-92
   PubMed Web of Science ®Google Scholar
• Froberg MK, Gerhart DZ, Enerson BE, Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues. Neuroreport 2001;12(4):761-5
   PubMed Web of Science ®Google Scholar
• Kiang TK, Ho PC, Anari MR, Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 2006;94(2):261-71
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2(6):347-56
   PubMed Web of Science ®Google Scholar
• Yoon HW, Giraldo EA, Wijdicks EF. Valproic acid and warfarin: an underrecognized drug interaction. Neurocrit Care 2011;15(1):182-5
   PubMed Web of Science ®Google Scholar
• Pursche S, Schleyer E, von Bonin M, Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 2008;3(3):198-203
   PubMedGoogle Scholar
• Bourg V, Lebrun C, Chichmanian RM, Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001;12(2):217-19
   PubMed Web of Science ®Google Scholar
• Oberndorfer S, Piribauer M, Marosi C, P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005;72(3):255-60
   PubMed Web of Science ®Google Scholar
• Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008;30(8):1385-407
   PubMed Web of Science ®Google Scholar
• Atmaca A, Al-Batran SE, Maurer A, Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007;97(2):177-82
   PubMed Web of Science ®Google Scholar
• Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329(19):1383-8
   PubMed Web of Science ®Google Scholar
• Verrotti A, D'Egidio C, Mohn A, Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011;52(2):199-211
   PubMed Web of Science ®Google Scholar
• Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47(2):332-72
   PubMed Web of Science ®Google Scholar
• Koenig S, Gerstner T, Keller A, High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinolysis 2008;19(5):375-82
   PubMed Web of Science ®Google Scholar
• Manohar C, Avitsian R, Lozano S, The effect of antiepileptic drugs on coagulation and bleeding in the perioperative period of epilepsy surgery: the cleveland clinic experience. J Clin Neurosci 2011;18(9):1180-4
   PubMed Web of Science ®Google Scholar
• Anderson GD, Lin YX, Berge C, Ojemann GA. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1997;87(2):252-6
   PubMed Web of Science ®Google Scholar
• Psaras T, Will BE, Schoeber W, Quantitative assessment of postoperative blood collection in brain tumor surgery under valproate medication. Zentralbl Neurochir 2008;69(4):165-9
   PubMedGoogle Scholar
• Wolff JE, Driever PH, Erdlenbruch B, Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 2010;116(3):705-12
   PubMed Web of Science ®Google Scholar
• Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000;22(1):62-5
   PubMed Web of Science ®Google Scholar
• Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther 1997;62(2):225-9
   PubMed Web of Science ®Google Scholar
• Chapman SA, Wacksman GP, Patterson BD. Pancreatitis associated with valproic acid: a review of the literature. Pharmacotherapy 2001;21(12):1549-60
   PubMed Web of Science ®Google Scholar
• Bohan TP, Helton E, McDonald I, Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001;56(10):1405-9
   PubMed Web of Science ®Google Scholar
• Samren EB, van Duijn CM, Koch S, Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint european prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38(9):981-90
   PubMed Web of Science ®Google Scholar
• Witt O, Schweigerer L, Driever PH, Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 2004;43(2):181
   PubMed Web of Science ®Google Scholar
• Rokes CA, Remke M, Guha-Thakurta N, Sorafenib plus valproic acid for infant spinal glioblastoma. J Pediatr Hematol Oncol 2010;32(6):511-14
   PubMed Web of Science ®Google Scholar
• van Breemen MS, Rijsman RM, Taphoorn MJ, Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 2009;256(9):1519-26
   PubMed Web of Science ®Google Scholar
• Weller M, Gorlia T, Cairncross JG, Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011;77(12):1156-64
   PubMed Web of Science ®Google Scholar
• Tsai HC, Wei KC, Tsai CN, Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg 2011. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ruben JD, Dally M, Bailey M, Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006;65(2):499-508
   PubMed Web of Science ®Google Scholar
• Su JM, Li XN, Thompson P, Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res 2011;17(3):589-97
   PubMed Web of Science ®Google Scholar
• Wolff JE, Boos J, Kuhl J. HIT-GBM: multicenter study of treatment of children with malignant glioma. Klin Padiatr 1996;208(4):193-6
   PubMedGoogle Scholar